Mumps Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 36 Published: March 31, 2022 Report Code: GMDGDHC22061IDB

Mumps is a contagious disease that leads to painful swelling of the salivary glands. Mumps is caused by a virus. The virus is spread from person to person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw, and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

The Mumps drugs in development market research report provide comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.

Key Routes of Administration in the Mumps Pipeline Products Market

The key route of administration in the Mumps pipeline products market is subcutaneous.

Key Molecule Types in the Mumps Pipeline Products Market

The key molecule types in the Mumps pipeline products market are live attenuated vaccine, vaccine, recombinant vector vaccine, and small molecule.

Mumps Pipeline Products Market Analysis by Molecule Type

Mumps Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Mumps Pipeline Products Market

The major companies in the Mumps pipeline products market are Beijing Minhai Biotechnology Co Ltd, Daiichi Sankyo Co Ltd, GlaxoSmithKline Plc, Shanghai King-Cell Biotechnology Co Ltd, Sinovac Biotech Ltd, and Zydus Lifesciences Ltd

Mumps Pipeline Products Market Analysis by Companies

Mumps Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key routes of administration Subcutaneous
Key molecule type Live Attenuated Vaccine, Vaccine, Recombinant Vector Vaccine, and Small Molecule
Major companies Beijing Minhai Biotechnology Co Ltd, Daiichi Sankyo Co Ltd, GlaxoSmithKline Plc, Shanghai King-Cell Biotechnology Co Ltd, Sinovac Biotech Ltd, and Zydus Lifesciences Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Mumps (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Beijing Minhai Biotechnology Co Ltd

    Daiichi Sankyo Co Ltd

    GlaxoSmithKline Plc

    Shanghai King-Cell Biotechnology Co Ltd

    Sinovac Biotech Ltd

    Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mumps – Overview

Mumps – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mumps – Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Mumps – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Daiichi Sankyo Co Ltd

GlaxoSmithKline Plc

Shanghai King-Cell Biotechnology Co Ltd

Sinovac Biotech Ltd

Zydus Lifesciences Ltd

Mumps – Drug Profiles

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

mumps vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

mumps vaccine – Drug Profile

Product Description

Mechanism Of Action

mumps vaccine – Drug Profile

Product Description

Mechanism Of Action

mumps vaccine – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Mumps – Drug Profile

Product Description

Mechanism Of Action

VN-0102 – Drug Profile

Product Description

Mechanism Of Action

Mumps – Dormant Projects

Mumps – Product Development Milestones

Featured News & Press Releases

Aug 02, 2021: GSK files for licensure of MMR vaccine in the US

Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Mumps, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Mumps – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022

Mumps – Pipeline by Daiichi Sankyo Co Ltd, 2022

Mumps – Pipeline by GlaxoSmithKline Plc, 2022

Mumps – Pipeline by Shanghai King-Cell Biotechnology Co Ltd, 2022

Mumps – Pipeline by Sinovac Biotech Ltd, 2022

Mumps – Pipeline by Zydus Lifesciences Ltd, 2022

Mumps – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Mumps, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.